Indaptus Q2 net loss $0.47/sh; cash $7.3M; raises $3M in August offering

Indaptus Therapeutics, Inc.

2024-Q2 EPS reported -$0.92

Net loss per share $0.47 for Q2 2024 vs $0.39 YoY; six-month loss $0.92 vs $0.89.
Cash and equivalents $7.3M at June 30, 2024; raised $3.0M (net ~$2.5M) on August 8 via registered direct offering and private placement.
Phase 1 Decoy20 trial: completed one month of weekly dosing in 3 patients at 3x10^7 dose; single dose at 7x10^7 completed.
Presented Decoy20 data at AACR and ASCO; CSO Michael Newman chaired STING & TLR Summit.
Cash runway expected into Q1 2025 based on current operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.